Search

The objective was to study the dynamics of B-type natriuretic peptide (BNP) and its relationship with hemodynamic parameters during on-pump coronary artery bypass grafting (CABG), and to evaluate the informativeness of the biomarker as a predictor of myocardial dysfunction.Materials and methods. The study involved 127 patients aged 59 [54–66.75] years with ischemic heart disease who underwent CABG. The BNP blood level was determined in the operating room at stages: I – before surgery (BNP1 ), II – at the end of surgery (BNP2 ). Hemodynamic parameters were analyzed at the same stages. Correlation analysis, logistic regression with the calculation of the odds ratio (OR) and 95% confidence interval (95% CI) and ROC analysis with the calculation of the area under the ROC curve (AUC) were used.Results. BNP1 blood level was 49 [25.6–91.6], BNP2 – 90 [47.8–140.2] pg/ml (p < 0.0001). BNP1 correlated with central venous pressure (CVP) at stage I (rho = 0.212; p = 0.017) and with pulmonary artery wedge pressure (PAWP) at stage II (rho = 0.204; p = 0.045). BNP2 correlated with PAWP at stage II (rho = 0.204; p = 0.045). BNP1 > 52.1 pg/ml was the predictor of ICU length of stay > 24 hours (OR 1.0290, 95% CI 1.0154– 1.0427, p < 0.0001, AUC 0.775), BNP1 > 71 pg/ml was the predictor of inotropic index > 5 c. u. (OR 1.0076, 95% CI 1.0015–1.0138, p = 0.014, AUC 0.705) and BNP1 > 90.8 pg/ml was the predictor of vasoactive inotropic index > 10 c. u. (OR 1.0070, 95% CI 1.0014–1.0126, p = 0.013, AUC 0.727). BNP2 > 67.5 pg/ml was the predictor of ICU length of stay > 24 hours (OR 1.0179, 95% CI 1.0073–1.0287, p < 0.0009, AUC 0.763), BNP2 > 94.3 pg/ml was the predictor of inotropic index > 5 c. u. (OR 1.0063, 95% CI 1.0010–1.0117, p = 0.020, AUC 0.713), BNP2 > 144 pg/ml was the predictor of intra-aortic balloon pumping (OR 1.0037, 95% CI 1 .0000–1.0074, p = 0.048, AUC 0.854), BNP2 > 159 pg/ml was the predictor of vasoactive inotropic index > 10 c. u. (OR 1.0072, 95% CI 1.0006–1.0139, p = 0.033, AUC 0.729) and BNP2 > 161 pg/ml was the predictor of early mortality in the ICU (OR 1.0040, 95% CI 1, 0000-1.0080, p = 0.049, AUC 0.845). Conclusion. In 78.7% of patients undergoing on-pump CABG, BNP blood level does not exceed the upper limit of normal; by the end of surgery, the biomarker level increases by 32.9 [17.7–62.0] pg/ml. Before and at the end of surgery, BNP values are weakly correlated with CVP and PAWP and do not correlate with other hemodynamic parameters. Before surgery, BNP blood level in the range of 52.1–90.8 pg/ml are predictors of ICU stay > 24 hours (AUC 0.775), inotropic scale > 5 (AUC 0.705) and vasoactive-inotropic scale > 10 c. u. (AUC 0.727). At the end of surgery, BNP > 67.5 pg/ml is associated with an ICU stay > 24 hours (AUC 0.763), and BNP > 90.4 pg/ml is associated with inotropic scale > 5 c. u. (AUC 0.713). The BNP, increased to 144.0–161.0 pg/ml, indicates severe myocardial dysfunction, including hemodynamic support with intra-aortic balloon pumping (AUC 0.854), vasoactive-inotropic scale > 10 c. u. (AUC 0.729) and the risk of early mortality in the ICU (AUC 0.845).

The objective was to study the occurrence of perioperative cardiovascular complications (CVС) and clinical and laboratory cardioprotection signs in patients treated with phosphocreatine infusion in intraoperative period of vascular surgery.Materials and methods. The study involved 204 patients with high cardiac risk (revised cardiac risk index > 2, risk of perioperative myocardial infarction or cardiac arrest > 1%) who underwent elective vascular surgery. The patients were randomly divided into two groups. Group I patients received intraoperative infusion of phosphocreatine at a dose of 75.9 [69.8–85.7] mg/kg during 120.0 [107.1–132.0] min. Group II was a control group. The occurrence of CVC, the blood level of the cardiospecific troponin I (cTnI) and N-terminal segment of natriuretic B-type prohormone (NT-proBNP) were analyzed. The data were statistically processed, using the Fisher’s exact test, Mann–Whitney test and logistic regression.Results. Perioperative CVС were recorded in 5 (4.9%) patients in group I and in 18 (17.6%) patients in group II (p = 0.007). Intraoperative administration of phosphocreatine was associated with a reduced risk of CVС: OR 0.2405, 95% CI 0.0856–0.6758, p = 0.007. The cTnI level in patients of groups I and II was 0.021 [0.016–0.030] and 0.019 [0.011–0.028] ng/ml (p = 0.102) before surgery, 0.025 [0.020–0.036] and 0.022 [0.015–0.039] ng/ml (p = 0.357) after surgery, 0.025 [0.020–0.031] and 0.028 [0.018–0.033] ng/ml (p = 0.531) before discharge from the hospital. At the same stages, the level of NT-proBNP was 233.5 [195.0–297.5] and 237.8 [171.3–310.1] pg/ml (p = 0.404), 295.5 [257.3–388.0] and 289.0 [217.5–409.5] pg/ml (p = 0.226), 265.5 [204.8–348.5] and 259.6 [171.0–421.6] pg/ml (p = 0.369).Conclusion. In patients with high cardiac risk undergoing vascular surgery, intraoperative phosphocreatine infusion at a total dose of 75.9 [69.8–85.7] mg/kg reduces the risk of perioperative CVC per 24%. Administration of phosphocreatine to patients with high cardiac risk during vascular surgery does not affect perioperative cTnI and NT-proBNP blood levels.

The objective was to study the occurrence of perioperative cardiovascular complications (CVС) and clinical and laboratory cardioprotection parameters in patients treated with dexmedetomidine infusion in perioperative period of vascular surgery.Materials and methods. The study involved 204 patients with high cardiac risk (revised cardiac risk index > 2, risk of perioperative myocardial infarction or cardiac arrest > 1%) who underwent elective vascular surgery. The patients were randomly divided into two groups. Group I patients received perioperative infusion of dexmedetomidine at a dose 0.40 [0.34–0.47] mg/kg/h during 7.0 [6.0–8.0]) hours. Group II was a control group. In the perioperative period, the occurrence of CVC, the blood level of the N-terminal fragment of the prohormone B-type natriuretic peptide (NT-proBNP) and cardiospecific troponin I (cTnI) were analyzed. The data were statistically processed, using the Fisher’s exact test, Mann–Whitney test and logistic regression.Results. Perioperative CVC without taking into account arterial hypotension were recorded in 3 (2.9%) patients in group I and in 14 (13.7%) patients in group II (p = 0.009). Arterial hypotension was recorded in 14 (13.7%) patients in group I and in 5 (4.9%) patients in group II (p = 0.051). Perioperative dexmedetomidine infusion reduced the risk of CVC, except for arterial hypotension (OR 0.1905, 95% CI 0.0530–0.6848, p = 0.011) and increased the risk of arterial hypotension (OR 3.5787, 95% CI 1.1254–11.3796, p = 0.031). The cTnI level in patients of groups I and II was 0.017 [0.011–0.024] and 0.019 [0.011–0.028] ng/ml (p = 0.196) before surgery, 0.02 [0.011–0.029] and 0.02 [0.015–0.039] ng/ml (p = 0.050) after surgery, 0.018 [0.014–0.024] and 0.028 [0.018–0.033] ng/ml (p = 0.0002) before discharge from the hospital. At the same stages, the level of NT-proBNP was 221.5 [193.3–306.5] and 237.8 [171.3–310.1] pg/ml (p = 0.572), 237.0 [205–303.5] and 289.0 [217.5–409.5] pg/ml (p = 0.007), 250.5 [198.8–302.0] and 259.6 [171.0–421.6] pg/ml (p = 0.933).Conclusion. In patients at high cardiac risk undergoing vascular surgery, perioperative dexmedetomidine infusion reduces the risk of a composite outcome including cardiac mortality, nonfatal myocardial infarction, myocardial ischemia, pulmonary embolism, stroke, hypertension, and arrhythmias, while the risk of arterial hypotension increases significantly. The perioperative dynamics of cTnI and NT-proBNP require further research. The start of dexmedetomidine infusion in 2.7% of cases is accompanied by severe bradycardia, requiring discontinuation of the infusion.

The objective was to study the occurrence of perioperative cardiovascular complications (CVС) and clinical and laboratory cardioprotection parameters in patients treated with an infusion of a succinate-containing drug during the intraoperative period of vascular surgery.Materials and methods. The study involved 120 patients with high cardiac risk (revised cardiac risk index > 2, risk of perioperative myocardial infarction or cardiac arrest > 1 %) who underwent elective vascular surgery. Patients were randomly divided into two groups. Patients of group 1 received intraoperative infusion of succinate-containing drug at a dose of succinate 0.35 [0.26–0.40] mg/kg/min– 1. Group II was a control group. In the perioperative period, the occurrence of perioperative CVC, the blood level of the N-terminal segment of natriuretic B-type prohormone (NT-proBNP) and cardiospecific troponin I (cTnI) were analyzed.Results. Perioperative CVC was registered in 11 (18.3 %) patients of group I and in 11 (18.3 %) patients of group II (p = 1.0). The level of NT-proBNP in patients of group I and group II was 207 [160–300] pg/ml and 229 [150.6–298.9] pg/ml (p = 0.817) before surgery, 234.2 [155.9–356] and 277 [177.7–404] pg/ml ( p = 0.207) after surgery and 240.5[149.3–306] and 235.5 [133–495.1] pg/ml ( p = 0.979) before discharge from the hospital. An increased level of cTnI after surgery was recorded in 4 (6.7 %) patients of group I and in 1 (1.7 %) patient ( p = 0.364) of group II.Conclusion. Intraoperative infusion of succinate-containing drug does not affect the occurrence of CVC in patients with high cardiac risk during vascular surgery. The succinate-containing drug does not affect the preoperative level of NT-proBNP and cTnI.

The objective was to study the dynamics of NT-proBNP blood level during the perioperative period of vascular surgery and to study the association of this biomarker level at the stages of treatment with developed cardiovascular complications (CVC).Materials and Methods. The study involved 129 patients aged 66 [61–70] years who underwent elective vascular surgery. NT-proBNP blood level was determined at stages: I – before surgery, II – 24 hours after surgery, III – before discharge from the hospital. Correlation analysis, logistic regression and ROC-analysis were used for data processing.Results. Median NT-proBNP (pg/ml) at stage I was 54[42–215], stage II – 149[63–298] (p1–2 = 0.0001) and stage III – 78[48–288] (p1–3 = 0.037). NT-proBNP blood level at stage I correlated with the biomarker level at stages II (rho = 0.558, p < 0.0001) and III (rho = 0.689, p < 0.0001). The biomarker was associated with CVC at all stages: I – OR 1.0048, 95% CI 1.0021–1.0074, p < 0.0001, AUC 0.825; II – OR 1.0040, 95% CI 1.0020–1.0060, p < 0.0001, AUC 0.820; III – OR 1.0026, 95% CI 1.006–1.0046, p = 0.015, AUC 0.687. At stage I, NT-proBNP > 218 pg/ml was a CVC predictor (sensitivity 82%, specificity 85%), this biomarker level was registered in 30 (23.2%) patients; at stage II, NT-proBNP > 281 pg/ml was associated with CVR (sensitivity 81%, specificity 80%), at stage III NT-proBNP > 158 pg/ml was associated with CCC (sensitivity 79%, specificity 65%).Conclusions. After vascular surgery, the median NT-proBNP value increases significantly, remaining within the reference limits, and does not de[1]crease until the patients discharge from the hospital. The perioperative NT-proBNP dynamics may differ in patients with different initial biomarker levels. In 23.2% of vascular surgical patients, the preoperative NT-proBNP blood level increased to a level of more than 218 pg/ml, indicating CVC risk (very good quality predictor model). After surgery, the level of NT-proBNP associated with CVC (very good quality model) exceeds 281 pg/ml. Prior to discharge of patients from the hospital, the association of NT-proBNP with CVC is characterized by a moderate quality model (AUC 0.687). The prognostic significance of the biomarker at this stage of surgical treatment needs further research.

The objective was to study the relationship between the increased preoperative N-terminal segment of B-type natriuretic peptide precursor (NT-proBNP) blood levels and the parameters of the heart ventricles function, as well as the conditions for coronary perfusion of their myocardium before and after on-pump aortic valve replacement.Materials and methods. The study involved 27 patients aged 57.7±2.5 years who underwent aortic valve replacement. NT-proBNP blood level was determined before surgery. The level of NT-proBNP > 1000 pg/ml was considered increased. Invasive hemodynamics, including the data of the right ventricle thermodilution volumetry, and transesophageal echocardiography data were analyzed at the stages: the 1st – after anesthesia induction, the 2nd – at the end of surgery. Logistic regression and ROC analysis were used for data processing.Results. Preoperative blood levels of NT-proBNP > 1000 (3163.0[2507.25–7319]) pg/ml were recorded in 55.6% of patients. At the 1st stage, the biomarker increased level was associated with increased index of left ventricular end-systolic volume (OR 1.0955, 95% CI 1.0097–1.1885, p = 0.028, AUC 0.903), decreased left ventricular ejection fraction (OR 0, 9447, 95% CI 0.8949–0.9973, p = 0.040, AUC 0.753) and area contraction fraction (OR 0.8868, 95% CI 0.8086–0.9726, p = 0.011, AUC 0.890), increased mean pulmonary artery pressure (OR 1.1824, 95% CI 1.0020–1.3952, p = 0.047, AUC 0.722), and increased transpulmonary gradient (OR 1.4497, 95% CI 1.0103–2.0802, p = 0.044, AUC 0.810), increased right ventricular stroke work index (OR 1.5151, 95% CI 1.0319–2.2246, p = 0.034, AUC 0.761), and decreased coronary perfusion gradients of the left (OR 0.8961–0.9241, 95% CI 0.8229–0.9459 – 0.8630–0.9896, p = 0.012–0.024, AUC 0.793–0.861) and right (OR 0.9519, 95% CI 0.9136–0.9918, p = 0.019, AUC 0.847) ventricles. At the 2nd stage, NT-proBNP blood values > 1000 pg/ml were associated with impaired left ventricular function, decreased mean arterial pressure (OR 0.9066, 95% CI 0.8264–0.9946, p = 0.038, AUC 0.761), and the vasopressor and inotropic support (OR 8.4000, 95% CI 1.2584–56.0694, p = 0.028, AUC 0.710).Conclusions. Prior to aortic valve replacement, the blood level of NT-proBNP > 1000 pg/ml is associated with a moderate decrease in the left ventricular ejection fraction and area contraction fraction, an increased left ventricular end-systolic volume with a normal end-diastolic volume, an increased index of right ventricular stroke work in combination with moderately increased mean pulmonary artery pressure and increased transpulmonary gradient, as well as a decreased coronary perfusion gradients. At the end of operations, increased NT-proBNP blood level is associated with signs of impaired left ventricular contractility, a tendency to arterial hypotension, and the vasopressor and inotropic support. Increased preoperative NT-proBNP blood level are not associated with right ventricular volumes and ejection fraction both before and after on-pump aortic valve replacement.

The objective was to study the relationship between the preoperative blood levels of the N-terminal segment of B-type natriuretic peptide precursor (NT-proBNP) and ultrasound and thermodilution indicators of cardiac function before and after on-pump surgery for aortic stenosis, as well as to evaluate the prognostic significance of the biomarker in relation to postoperative myocardial dysfunction.Materials and methods. The study involved 27 patients aged 57.7±2.5 years who underwent aortic valve replacement. NT-proBNP level was determined before surgery. The indicators of invasive hemodynamics and transesophageal echocardiography were analyzed at stages: I – after anesthesia induction, II – at the end of surgery. Correlation analysis, logistic regression and ROC analysis were used.Results. The preoperative NT-proBNP level was 2002.0 [540.8–4001.5] pg/ml. At I stage, NT-proBNP correlated with mean pulmonary artery pressure (rho = 0.468; p = 0.014), indices of left ventricular function (rho = –0.509; p = 0.007), end-diastolic and end-systolic volumes (rho = 0.737–0.757; p 2000 pg/ml was a predictor of the left ventricular area contraction fraction 9 cm2/m2 (OR 1.0007, 95% CI 1.0001–1.0013, p = 0.027, AUC 0.886), vasoactive-inotropic score > 10 (OR 1.0006, 95% CI 1.0001–1.0012, p = 0.032, AUC 0.876), duration of sympathomimetic therapy > 24 h (OR 1.0001, 95% CI 1.0000–1.0003, p = 0.049, AUC 0.889).Conclusions. NT-proBNP blood level was increased in 66.7% of patients with aortic stenosis before surgery. Moreover, the biomarker level directly correlates with the mean pulmonary artery pressure, the indices of end-diastolic and end-systolic volumes, end-diastolic and end-systolic areas of the left ventricle, and it inversely correlates with the left ventricular stroke work index, ejection fraction and left ventricular area contraction fraction. The preoperative NT-proBNP level was a predictor of the postoperative decrease to the pathological level of the ejection fractions and left ventricular area contraction, an increase in the left ventricular end-systolic area index, intensive and prolonged sympathomimetic therapy. Myocardial dysfunctions were most pronounced in patients with biomarker levels above 2000 pg/ml.

The objective was to perform a comparative analysis of the information content of potential predictors of cardiovascular complications of various types in patients operated on for vascular diseases. Materials and Methods. We examined 129 patients aged 66 [61–70] years who underwent elective vascular surgery. We analyzed comorbidity, general clinical indicators, special cardiac risk indices and biomarkers: N-terminal segment of B-type natriuretic peptide prohormone (NT-proBNP) and cardiospecific troponin I. We used logistic regression and ROC analysis. Results. 21 (16.3 %) perioperative cardiovascular complications were registered in 17 (13.2 %) patients. In one-factor regression, the predictors of cardiovascular complications were coronary heart disease (OR 4.5904; 95 % CI 1.3119–5.9340; p = 0.0171), combination of coronary heart disease and chronic heart failure (OR 2.9419; 95 % CI 1.0140–8.5350; p = 0.047), ASA class > 3 (OR 2.9402; 95 % CI 1.0304–8.3899; p = 0.0438), high cardiac risk surgery (OR 3.4741; 95 % CI 1.1162-10.8126; p = 0.0316), Lee cardiac risk index (OR 2.2353; 95 % CI 1.2842–3.8911; p = 0.0045), the American College of Surgeons cardiac risk index for assessing the risk of perioperative myocardial infarction or cardiac arrest (OR 1.5312; 95 % CI 1.0927–2.1456; p = 0.0133) and the preoperative level of the N-terminal prohormone B-type natriuretic peptide (NT-proBNP) (OR 1.0048; 95 % CI 1.0021–1.0074; p = 0.0004). In multivariate regression, the predictors of cardiovascular complications were high-risk cardiac surgery (OR 5.7439; 95 % CI 1.1027–29.9181; p = 0.0379) and NT-proBNP (OR 1.0044; 95 % CI 1.0015–1.0073; p = 0.0033). The biomarker level > 218 pg/ml discriminated against cardiovascular complications with sensitivity of 82.4 % and specificity of 85.3 % (AUC 0.825; 95 % CI 0.747–0.887; p < 0.0001). Conclusion. In vascular interventions, the most significant predictors of cardiovascular complications are high-risk cardiac surgery and the preoperative level of NT-proBNP > 218 pg/ml with a sensitivity and specificity level exceeding 80 %.

Subjects and Methods. The study involved 35 vascular surgery patients of varying degrees of cardiological risk. Blood specimens were collected from each patient at 3 time-points: 1. prior to surgery (NT-proBNP1), 2 — after the procedure (NT-proBNP2), 3 — before the discharge from the hospital (NT-proBNP3). Each specimen was split into equal aliquots for biomarker quantification using two different techniques (ELISA using domestic reagents — for the 1st series of analyses, and ICLA using an imported kit — for the 2nd series). Perioperative cardiovascular complications were recorded. The consistency of the measurement results obtained by two different methods was evaluated using the Bland–Altman technique. A discrimination ability of independent variables in relation to a binary dependent variable was studied using ROC analysis.Results. In the 1st series, ranges of the biomarker were as follows: NT-proBNP1 — 24–774 pg/ml, NT-proBNP2 — 41.2–889.1 pg/ml, NT-proBNP3 — 39.3–1013.3 pg/ml. In the 2nd series, NT-proBNP1 was 31.2–2087.0 pg/ml, NT-proBNP2 — 32.5–3754.0 pg/ml, NT-proBNP3 — 34.1–2728.0 pg/ml. In the Bland–Altman analysis, 97.03% of the values fell within the lower and upper limits of consistency (±1.96 SD of the average difference), which indicated comparability of the results in the series, but the values of NT-proBNP in the 1st series were lower than in the 2nd ones. Cardiovascular complications were registered in 3 (8.5%) patients. In the 1st series, NT-proBNP1 > 218 pg/ml predicted cardiovascular complications with a sensitivity of 66.7% and a specificity of 81.3% (AUC 0.844, 95% CI 0.681–0.944, P = 0.0003). In the 2nd series, NT-proBNP1 > 315 pg/ml predicted cardiovascular complications with a sensitivity of 66.7% and a specificity of 75.0% (AUC 0.828, 95% CI 0.663–0.934, P = 0.001).Conclusion. The domestic ELISA kit for solid-phase enzyme immunoassay proved its clinical informativeness for quantitation of NT-proBNP demonstrating its value for diagnostic and prognostic purposes, or scientific studies. The novel domestic technique provides consistently reproducible results, although with lower reference values as compared to the standard immunochemiluminescence assay.

The objective: to study changes and prognostic significance of the blood NT-proBNP in the patients with pulmonary sepsis.Subjects and Methods. The study included 34 patients aged 54.5 ± 2.9 years with pulmonary sepsis or septic shock. Lethality in the intensive care unit (ICU) was 47.1%. NT-proBNP, procalcitonin (PCT) levels, blood lactate and hemodynamic parameters were registered on the 1st day (stage 1) and on the 4th-5th day of the ICU stay (stage 2). Hemodynamics was assessed through transpulmonary thermodilution. The differences were considered statistically significant at p < 0.05.Results: At stage 1, NT-proBNP level was 5,220 [1,380‒17,850] pg/ml, did not decrease (p = 0.726) at stage 2 and amounted to 1,760 [631‒847] pg/ml. At stage 1, NT-proBNP correlated with extravascular lung water index (rho = 0.445; p = 0.038) and systolic pulmonary artery pressure (rho = 0.414; p = 0.023). At stage 2, NT-proBNP correlated with PCT (rho = 0.569; p = 0.003), blood lactate (rho = 0.525; p = 0.001), and mean arterial pressure to norepinephrine dosage ratio (rho = -0.422; p = 0.035). At stage 1, NT-proBNP was no predictor of lethality in the ICU: OR 1.0000; 95% CI 1.0000-1.0001. At stage 2, NT-proBNP > 4,260 pg/ml (sensitivity 87.5%, specificity 94.4%) was a predictor of lethality: OR 1.0004, 95% CI 1.0000-1.0008, p = 0.046 (AUC 0.893, 95% CI 0.732-0.974). Any increase of NT-proBNP level (> 0 pg/ml) between stages 2 and 1 was a predictor of lethality (sensitivity 87.5%, specificity 94.4%): OR 119.0, 95% CI 9.7432‒1,453.4241, p = 0.0002 (AUC 0.903, 95% CI 0.751-0.977).Conclusion: Patients with pulmonary sepsis are characterized by a significant increase of blood NT-proBNP. At stage 1, the biomarker correlated with pulmonary hypertension and moderate pulmonary edema and was no predictor of lethality. At stage 2, NT-proBNP correlated with the indices of infection and sepsis severity (procalcitonin, blood lactate, and mean arterial blood pressure/norepinephrine dosage ratio). At this stage, NT-proBNP levels greater than 4,000 pg/mL and/or any degree of increase in blood levels of the biomarker were both sensitive and specific predictors of a lethal outcome. Specific features of etiopathogenesis of BNP hyperproduction in pulmonary sepsis make it difficult to interpret the elevation of NT-proBNP as an indicator of septic cardiomyopathy but does not reduce its value as a sensitive and specific predictor of lethality.

The objective: to study information value of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in the cardiac risk assessment in abdominal oncological surgery.Subjects and Methods. 94 patients of 68 [62‒73] years old who underwent elective surgery were examined.Results. Cardiovascular comortbidity was diagnosed in 69 (73.4%) patients. 11 (11.7%) perioperative cardiovascular complications were registered. Cardiac mortality was 4.3%. Hematological indices were not associated with cardiovascular diseases (NLR: OR = 0.59‒1.42; 95% CI 0.14‒2.60; p = 0.29‒0.74, PLR: OR = 0.99‒1.00; 95% CI 0.97‒1.01; p = 0.31‒0.99). NLR and PLR were not predictors of cardiovascular complications (OR = 0.67; 95% CI 0.19‒2.37; p = 0.46 and OR = 1.00; 95% CI 0.99‒1.01; p = 0.68) and cardiac death (OR = 0.21; 95% CI 0.01‒8.05; p = 0.23 and OR = 0.99; 95% CI 0.98‒1.01; p = 0.79).Conclusion. NLR and PLR cannot be recommended for the cardiac risk assessment in abdominal oncological surgery.

The objective: to study hemodynamic and clinical effects of levosimendan depending on the clinical outcome in patients with sepsis and impaired cardiac pumping function.Subjects and Methods. the retrospective study involved 31 patients of 52.7 ± 2.8 years old with sepsis or septic shock which were treated with levosimendan at the dose of 0.16 [0.15‒0.17] mg/kg (0.11 [0.1‒0.12] μg × kg-1 × min-1) on days 1–4 of ICU stay. The patients were divided into the following groups: Group 1 ‒ survivors (n = 19) and Group 2 – non-survivors (n = 12). Central hemodynamics was assessed through transpulmonary thermodilution. The differences were considered statistically significant at p < 0.05.Results. Most of the hemodynamic parameters and vasopressors and inotropes doses had no differences between the groups before levosimendan administration. There were no differences in the cardiac index (3.8 ± 0.3 vs 3.5 ± 0.3 L/min/m2; p = 0.479) between the groups following levosimendan administration, however, Group 1 demonstrated the following parameters to be lower versus Group 2: central venous pressure (7 ± 0.7 vs 11 ± 1 mm Hg; p = 0.005), blood lactate (1 [0.9‒1.8] vs 2.4 [2.2‒3.3] mmol/L; p = 0.04), norepinephrine dosages (0.2 [0.15‒0.35] and 0.5 [0.4‒0.6] ng/kg/min; p = 0.023 ), global end-diastolic volume index (693 [688‒28] vs 870 [779‒961] mL/m2; p =0,0009) and the level of NT-proBNP (1,590 [1,080‒3,160] vs 35,000 [21,400‒35,000] pg/mL; p = 0,0001). Global heart ejection fraction (23 [21‒27] vs 15 [12‒20]%; p = 0.015) and heart function index (6 [5‒8] vs 3 [ 3-4] min-1; p = 0.003) ) were higher in Group 1 versus Group 2. APACHE II >19 (AUC 0.906; p < 0.0001), SOFA > 9 (AUC 0.805; p = 0.0002); heart rate > 114 min-1 (AUC 0.755; p = 0.0095), and index of total peripheral vascular resistance < 1,700 dyn × s × cm-5 × m2 (AUC 0.806; p = 0.001) before levosimendan administration were the independent predictors of death in patients treated with levosimendan.Conclusion: non-survivors patients with sepsis had significantly higher APACHE II and SOFA scores, higher heart rate and lower index of total peripheral vascular resistance before levosimendan infusion. In survivors levosimendan infusion at a standard dose led to a significant improvement in the heart pumping function accompanying by global heart ejection fraction and heart function index increasing and NT-proBNP decreasing. In non-survivors such favorable central hemodynamics changes did not occur, although the cardiac index increased after inodilator administration. Further studies of levosimendan efficacy in patients with sepsis of varying severity are advisable. It is necessary to specify the indications and contraindications for levosimendan administration to patients with sepsis.

The objective: to study the prognostic significance of the ratio of the absolute number of neutrophils to lymphocytes (NLR) and platelets to lymphocytes (PLR) in assessing the risk of cardiovascular complications in non-cardiac surgical interventions.Subjects and Methods. 85 patients aged 66 [61‒70] years who underwent elective vascular surgery were examined.Results. Concomitant circulatory diseases were diagnosed in 98.8%. PLR < 91.2 with the sensitivity of 60% and the specificity of 67.8% was associated with diabetes mellitus (AUC – 0.686; 95% CI 0.576‒0.783, p = 0.0022). Cardiovascular complications were registered in 9.3% of patients. NLR was an independent predictor of cardiovascular complications: OR – 5.216; 95% CI 1.246‒21.826, p = 0.005. NLR > 2.1 discriminated cardiovascular complications with the sensitivity of 75% and specificity of 75% (AUC – 0.827; 95% CI 0.690–0.921; p = 0.004). PLR was also a predictor of cardiovascular complications: OR – 1.0111; 95% CI 1.0001–1.0223; p = 0.027. PLR > 105.5 allowed identifying patients with NT-proBNP > 650 pg/ml with the sensitivity of 75.0% and the specificity of 61.8% (AUC – 0.740; 95% CI 0.630‒0.832; p = 0.0308).Conclusion. NLR and PLR can be used to identify patients with increased cardiac risk when undergoing vascular surgery. Further research in this field is advisable.

Aim of the study: to determine the predictive value of central hemodynamic parameters in relation to mortality and evaluate their potential acceptability for goal-directed therapy during days 1-4 of treatment in patients with sepsis.Material and methods. The results of investigation and treatment of 62 patients aged 50.9±2.13 years with abdominal sepsis were analyzed. The patient severity on admission to the intensive care unit was 13 [10-15] on the APACHE II scale, 8 [6.75-9.25] on the SOFA scale. Lethal outcome 15.6±1.4 days after admission occurred in 19 (31%) patients. Central hemodynamic parameters were studied by transpulmonary thermodilution according to the standard technique. Infusions and administration of sympathomimetic drugs were performed according to Sepsis-3 guidelines. Statistical analysis was performed using logistic regression and ROC analysis.Results. The median values of the main circulatory parameters during days 1-4 of sepsis treatment were within normal ranges. Cardiac index, afterload-related cardiac performance, global cardiac ejection fraction and cardiac function index were predictors of mortality at all stages of treatment. However, the first three parameters did not provide either sufficient model quality at the study stages or a stable cutoff value with acceptable sensitivity and specificity. The cardiac function index maintained good model quality (area under the ROC curve 0.708-0.753) and a stable cutoff value (≤5.75 to ≤5.81 min-1) with acceptable and balanced sensitivity and specificity of about 70% at all study stages.Conclusion. The cardiac index, afterload cardiac performance, global cardiac ejection fraction and cardiac function index during days 1-4 of intensive care of sepsis are predictors of lethal outcome. At the same time, only the cardiac function index maintains good model quality and consistent cut-off point value with acceptable sensitivity and specificity at all stages of the study. The feasibility of using the cardiac function index as one of the parameters of goal-directed therapy aimed at cardiovascular function improvement in sepsis needs further investigation.

The objective: to analyze the incidence and spectrum of cardiovascular complications within 12 months after noncardiac surgery, as well as to assess the association of preoperative values of various cardiac risk indices (CRI) and other potential risk factors with the actual development of complications.Subjects and Methods. We analyzed data of medical records and telephone interviews of 141 patients aged 65 [60-71] years who had undergone non-cardiac surgery a year before the interview The operations were low risk in 13.5% of observations, medium risk in 64.5%, and high risk in 22%. A retrospective calculation of the Revised CRI (RCRI), Individual CRI (Khoronenko CRI), and the American College of Surgeons Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA) was performed.Results. Cardiac events (myocardial infarction, decompensation of chronic heart failure, new arrhythmias, stroke, and/or the need to prescribe or escalate the dose of cardiovascular drugs and/or hospitalization for cardiac indications, and/or death from cardiovascular diseases) within 12 months after elective noncardiac surgeries were detected in 27.7% of cases, and in 2.1% of patient's death occurred due to cardiac disorders. Predictors of cardiac events were concomitant ischemic heart disease (OR = 2.777; 95% CI 1.286-5.966; p = 0.0093) and chronic heart failure (OR = 2.900; 95% CI 1.224-6.869; p = 0, 0155), RCRI (OR = 1.886; 95% CI 1.2-8-2.944; p = 0.005), Khoronenko CRI (OR = 3254.3; 95% CI 64.33-164,638; p = 0.0001), MICA (OR = 1.628; 95% CI 1.156-2.292; p = 0.005), creatininemia on the first postoperative day (OR = 1.023; 95% CI 1.010-1.061; p = 0.005), and propensity for bradycardia during surgery (OR = 0.945; 95% CI 0.908-0.983; p = 0.005). Combined analysis of Khoronenko's CRI and postoperative creatininemia provided a very good model: area under the ROC-curve - 0.823 (95% CI 0.728-0.641; p = 0.0002).Conclusion. All studied CRIs can be used to predict posthospital cardiac events; however, the most promising is a joint assessment of Khoronenko's CRI and postoperative creatinemia.

The objective: based on publications to provide up-to-date information on the frequency, basic variants and predictive significance of cardiovascular complications of the coronavirus infection caused by SARS-CoV-2.Results: the article identifies variants of cardiovascular disorders in COVID-19 caused by various comorbidities in particular hypertension, specific virus-associated myocardial damage, and side effects of medications. It analyzes the role of angiotensin-converting enzyme 2 type II receptors during infection with the coronavirus and potential changes in the renin–angiotensin–aldosterone system including in patients receiving angiotensin-converting enzyme inhibitors or blockers of angiotensin receptors. The data on the frequency and prognostic role of arrhythmias, virus-associated myocardial damage and heart failure, the risk of ischemia, and myocardial infarction are presented. The adverse cardiovascular events of drugs of different groups prescribed for treatment of COVID-19 and possible drug interactions are described. The current recommendations for cardiotonic and cardioprotective therapy in patients with cardiovascular complications are analyzed.Conclusion. The SARS-Cov-2 virus has a pronounced cardiac tropic effect which requires maximum cardiac alertness in the treatment of patients in this category, timely use of electrocardiography, echocardiography, control of biomarkers of myocardial damage and tension, as well as a reasonable use of cardiotonic and cardioprotective drugs.

The objective: to present current information about definitions, etiopathogenesis, clinical, laboratory and hemodynamic manifestations of septic cardiopathy, based on published data and the results of our own research.Results: septic cardiopathy is the most important pathogenetic component of sepsis, and cardiac dysfunction makes a significant contribution to its outcomes. It is found out that after staying in the intensive care unit for 3-4 days, the level of the inactive part of the precursor of the B-type natriuretic peptide (NT-proBNP) > 3,450 pg/ml indicates of the risk of death: area under ROC curve (AUC) 0.708 (p = 0.0041), sensitivity 63.6%, and specificity 66.7%. At the same time, NT-proBNP > 5,250 pg/ml is associated with the use of inotropic drugs: AUC 0.769 (p = 0.0007), sensitivity 76.9%, specificity 79.0%. The article describes the detection of septic cardiopathy using transpulmonary thermodilution and calculation of such indices as afterload-related cardiac performance and cardiac function index. Data on the age-related parameters of central hemodynamics and risk of pathological decrease in certain blood circulation indices characteristic of older patients are presented. The article discusses the feasibility of treating septic cardiopathy as a variant of acute heart failure, which can be manifested not only by a decreased systolic function (low left ventricular ejection fraction) but also by increased end-diastolic pressure in the ventricles (diastolic dysfunction) with a normal left ventricular ejection fraction.

The objective: based on the published data to describe the conceptual issues of the problem of perioperative cardiac complications in non-cardiac surgery.Results: changes made to international guidelines over the past 3–4 years based on evidence-based studies and meta-analyzes have been analyzed. The article presents data on the etiopathogenesis of various postoperative cardiac complications, assessment of their risk based on the evaluation of functional activities of patients, cardiac risk indices, and modern biomarkers (B-type natriuretic peptides, cardiospecific troponins). The contemporary recommendations on adjuvant pharmacological cardioprotection and rational pharmacotherapy in the perioperative period are analyzed. The article describes specific parameters of diagnostic, treatment and prevention tactics in patients with coronary heart disease, hypertension, chronic heart failure, heart defects, and implanted electronic devices. It concludes that the implementation of the comprehensive strategy aimed at the reduction of risk of pulmonary complications should ensure the decrease in their frequency and mortality due to them.

Purpose of the study: to investigate the epidemiology of sepsis in patients with different locations of the infection focus, who were admitted to the intensive care unit (ICU) of a multi-specialty hospital in 2014 and 2016.Material and methods. A retrospective analysis of examination and treatment of 860 patients admitted to ICU of a multi-specialty hospital with the diagnosis ‘sepsis’ in 2014 and 2016 was carried out. Sepsis was diagnosed pursuant to the Sepsis-2 Guidelines and verified by blood procalcitonin test. The gender, age, main diagnosis, patient’s severity at the time of admission to ICU, duration in ICU, and peculiarities of intensive care and outcomes were studied.Results. Sepsis was diagnosed at admission in 2014 in 361 (8.6%) patients out of 4175 patients, in 2016 — in 499 (10.5%) out of 4726 patients who were admitted to ICU and had infection foci of different location. Abdominal sepsis was diagnosed in 72.3% of patients, pulmonary — in 19.7%; in 8% of patients, sepsis complicated the terminal stage of various, mostly oncological, diseases. In 2016, sepsis detectability at admission to ICU increased by 22.1% vs. the 2014 level assumed as 100% (χ2=9.281; P=0.003). In case of the abdominal sepsis, mortality amounted to 50.3% and was not different from mortality in pulmonary sepsis — 52.1% (χ2=0,163; P=0.687). The ICU in-patient duration in case of pulmonary sepsis was considerably longer than in case of abdominal. The age was a predictor of mortality in case of abdominal sepsis (the age older than 65 years predicted the risk of lethal outcome with sensitivity equal to 58.8% and specificity equal to 59.9%), which was not true for pulmonary sepsis. The mortality prognosis during abdominal sepsis was improved by combined analysis of the SOFA score and patient’s age at admission: AUROC of the combined index was equal to 0.816 (95%-confidence interval: 0.783–0.846). Depending on the infection focus location, specificity of influence rendered on mortality by different clinical indices and management methods was determined.Conclusion. Patients admitted to ICU with sepsis represent a group of a high mortality risk amounting to 50% approximately. During chronological analysis, sepsis detectability increases but mortality does not change. Patients with pulmonary sepsis at admission to ICU are characterized by a greater severity of condition due to multiple organ failure than in case of abdominal sepsis; in such patients it is impossible to predict the risk of mortality based on APACHE II and SOFA score. Taking into account heterogeneity of the sepsis patient population, deepening of the knowledge about peculiarities of pathogenesis and clinical pattern of abdominal and pulmonary sepsis is the basic requirement for improvement of the results of treatment of this complication.

The second part of the overview presents and analyzes the current data on the methods of adjuvant pharmacological cardioprotection and possibilities of optimizing the anesthetic support and perioperative monitoring in high cardiac risk patients. Amendments made in international guidelines for the last 2–3 years on the basis of conclusive studies and meta-analyses have been examined. Cardioprotection mechanisms and information about its implementation in real clinical practice have been analysed. It has been shown that by no means all drugs under discussion can be widely used for prophytlactic purposes. Contemporary evidencebased recommendations concerning the optimization of anesthetic support and perioperative monitoring are given. A conclusion has been made that practical implementation of a comprehensive strategy aimed at reduction of the risk of cardiac complications might ensure decrease of both the incidence of severe cardiac complications and mortality due to them.

The lecture is devoted to the current state of pharmacological cardiac protection in patients with a high cardiac risk undergoing non-cardiac and cardiac surgery with cardiopulmonary bypass. It describes the main etiopathogenetic mechanisms of ischemic reperfusion myocardial damage. The possible cardioprotection mechanisms when using inhalation anesthetics, β-adrenoreceptor blocking agents, calcium channel blockers, statins, nitrates, α2 -agonists, ACE inhibitors and sartans, levosimendan, phosphocreatine, and glucose-insulin-potassium mixture are analyzed. New research data are reviewed, including recent meta-analyses and extensive randomized studies aimed to assess the efficacy of the above medicines. It presents contemporary clinical guidelines on the use of pharmacological cardioprotection in various clinical situations. It has been concluded that the range of drugs recommended for cardioprotection is constantly changing in accordance with latest data, and updating the scientific information on this issue is an important to improve the professional competence of anesthesiologists and emergency physicians.

The purpose of this paper is to provide scientific and practical information on assessment of the risk of myocardical damage development after noncardiac operations (NOMD): ischemia or myocardial infarction (MI), and/or heart failure (HF) and their prevention in adult patients. This overview of literature consists of two parts. The first part analyzes epidemiology, etiopathogeneis, and POCC risk prediction methods; the second part describes the possibilities of adjuvant pharmacological cardioprotection and approaches to optimizing anesthesiological support of operative interventions in high cardiac risk patients.The problem of perioperative cardiac complications in noncardiac surgey is one of relevant complex issues of contemporary medicine. In line with contemporary views, NOMD is now regarded as a separate variant of a pathological process in the heart muscle. According to extensive studies, about 40% of mortality of adult patients during non-cardial operative inverventions are caused by various NOMD and/or HF. The problem under discussion is particularly relevant when medical assistance is rendered to elderly patients.

Introduction. The total number of patients with chronic heart failure in Russia had reached 15 million by 2016, including 6 million of those with the end-stage heart failure. Currently, heart transplantation (HT) provides the only possible method of a definite treatment of the disease, which allows a significant steady and long-term improvement of patient's quality of life. The purpose of this article was to review the experience of heart transplantation in a multidisciplinary medical institution over an 8-year period.Material and methods. Since September 2009, more than 300 patients have been studied for the presence of indications for heart transplantation in the Department of Urgent Cardiology, Assisted Circulation and Heart Transplantation of the Sklifosovsky Research Institute for Emergency Medicine. Eighty of all the screened potential recipients were included in the waiting list, and by the end of 2017, heart transplantations had been performed in 70 of them; the mean waiting time for transplantation was 93 ± 79 days.Results. The graft ischemia time averaged 174 ± 28 minutes (97 to 250 minutes). The graft ischemia time was 187 ± 36 minutes with the biatrial technique and 169 ± 24 minutes with bicaval technique. That parameter made 184 ± 23 minutes for a distant organ retrieval, while for a local organ retrieval it was 155 ± 29 minutes. By the end of 2017, of 70 cardiac transplant recipients enrolled in the analyzed group, 31 patients (44%) had died, 12 of whom during their hospital stay (hospital mortality was 18%). The main cause of death was the multiple organ failure syndrome in the early postoperative period, and infectious complications in the later period.Conclusion. The advantage of establishing the organ transplantation center (particularly for heart transplantation) in a multidisciplinary medical care facility lies in reduced donor organ ischemia time and starting treatment of complications without delay. The number of infectious complications, as well as complications associated with acute cellular rejection and coronary artery disease of the transplanted heart can be reduced by creating a regional system ensuring the targeted work with post transplant patients.

The objective of the study: to find early hemodynamic predictors of a lethal outcome of abdominal sepsis.Methods. 44 patients with abdominal sepsis with no signs of septic shock were enrolled into a retrospective study. The age of patients made 48.7 Ѓ} 2.26 years old; the severity of state according to APACHE II was 12.50 Ѓ} 0.55 scores, and as per SOFA ‒ 8 [6; 10]) scores. Hemodynamics was assessed through transpulmonary thermodilution.Results. During the first 24 hours, the following rates were the most sensitive and specific in respect of a lethal outcome: cardiac function index (odds ratio – 0.582; 95%CI 0.388-0.872; p = 0.008), and cardiac power index (odds ratio – 0.027; 95%CI 0.001-0.6; p = 0.022). The same results were observed in 4-5 days of treatment. At different stages of the study, the following rates demonstrated stable predictive significance: cardiac index (CI), systolic output index, global ejection fraction; and the area under ROC-curves (AUROC) for these rates was compatible with AUROC as per SOFA.Conclusion: The investigation of the after-load dependent relative cardiac efficiency proved that the normal values of CI could be predictive of an unfavorable sepsis outcome if after-load dependent relative cardiac efficiency was < 80%. It is sensible to define individual target values of cardiac hemodynamics, which significance is clinically proved in case of sepsis.

The literature review presents an analysis of publications on the use of a selective α2-adrenergic receptor agonist (α2-AR) dexmedetomidine as a cardioprotector in cardiosurgical interventions. It summarizes historical aspects of the introduction of α2-AR agonists in the intensive care practice. It analyzes possible mechanisms of the cardioprotective effect of dexmedetomidine (central sympatholysis, favorable effects on the coronary circulation and relief of the coronary steal syndrome in originally ischemized areas of the myocardium, antiinflammatory and antioxidant effects, and prevention of apoptosis activation). Data from experimental studies of dexmedetomidine cardioprotection were analyzed. Results of clinical studies, including data of metanalyses, were discussed. It dwells on data on the favorable effect of dexmedetomidine on various parameters of the postoperative period, including a decreased risk of delirium, general complications of cardiosurgical interventions, and the mortality rate in patients. It presents data on cardioprotective properties of dexmedetomidine in surgical patients who undergo noncardiac interventions, particularly vascular ones, including high risk surgeries in the aorta. A comparative analysis of results of clinical trials studying the dexmedetomidine cardioprotection during surgeries with extracorporeal circulation was performed. A range of pharmacological effects of dexmedetomidine during anesthesiological support of cardiac surgeries, including those in elderly and senile patients, was described. It has been concluded that the dexmedetomidine cardioprotection in the various fields of surgery is obviously very promising.

The literature review presents an analysis of publications describing the use of a glucose%insulin mixture as a cardioprotective agent in acute myocardial infarction and in cardiac surgeries with extracorporeal circulation (ECC). It summarizes historical aspects of implementation of the glucose%insulin therapy in cardiology and car%diac surgery. Possible mechanisms of action of the glucose-insulin-potassium mixture in acute ischemia and myocardial infarction were analyzed (normalization of electrical processes on the cardiomyocyte membrane, replenishment of metabolic substrates and increased production rate of adenosine triphosphoric acid due to glycolysis, decreased intensity of non%esterified fatty acid oxidation, decreased apoptosis, etc.). It discusses results of clinical studies evaluating prescription of the mixture for acute myocardial infarction, including data from metaanalyses. It demonstrated that the role and the clinical efficacy of the preventive and therapeutic measure under consideration in acute myocardial infarction are still the subject of discussion and require further research. It also analyzed modern concepts explaining the cardioprotective effects of insulin and glucose during surgeries with ECC (decreased insulin resistance, activation of anaplerosis, stimulation of intracellular signaling pathways maintaining the viability of cells, reduction of the severity of systemic inflammatory response, immunomodulatingeffect, etc.). Review discusses results of clinical studies including data from randomized clinical trials and metaanalyses performed over the last 5 years that demonstrated the absence of the effect of the glucose%insulin therapy on the hospital mortality. Various studies demonstrated its positive effects including decreased incidence of peri%operative myocardial infarctions and intensity of inotropic support, increased values of postoperative cardiac index, decreased duration of postoperative mechanical ventilation and ICU stay, etc. Review concludes that the interest to the therapeutic and preventive use of the glucose%-nsulin mixture in both emergency cardiology and cardiac surgery has been revived recently.

The aim of the study was to determine the correlation between blood levels of Nterminal portion of the inactive precursor of natriuretic peptide of Btype (NTproBNP) and hemodynamic, clinical and laboratory parameters in the course of intensive treatment of patients with severe communityacquired pneumonia (CAP).Materials and methods. The study included 12 patients (10 men and 2 women) with severe CAP, age 25—88 (51.5 (41.25; 69)) years. The severity of the condition was as follows (averages and percentiles): on a scale of CURB65 — 3—5 (4; 4,5) scores, APACHE II — 16—33 (23 (18.75; 25)) scores, SOFA — 6—16 (10 (9; 12.75)) points. Concentartions of NTproBNP in venous blood 24—36 h post admission and on day 5 of treatment were determined by analyzer Dimension Xpand Plus (Siemens).Results. Within 24—36 hours after the admission concentration of NTproBNP was 783.5 (460.75; 4150.25) pg/ml. The content of the biomarker remained higher than in norm in 66.7% of patients. By the 5th day the concentration of the biomarker was 537 (376.25, 1334) pg/ml. In surviving patients (66.7%), the concentration of NT proBNP was decreasing (P=0.008) to day 5 of treatment from 918 (560, 8501) to 391 (341, 1010) pg/ml. CAP patients who did not survived later (32.3%) exhibited no decrease of the biomarker concentration. Significant correlation between NTproBNP on admission to ISU and index of total peripheral vascular resistance on day 2 of intensive treatment (r=0.63; p

In the next 20 years, the aging population will be a major factor affecting the characteristics of perioperative anesthesia tactics. Domestic researchers have reported that the incidence of cardiac complications after general surgical procedures in patients with middle and old age is 9.1%, and mortality in these complications reached 45.5%. Analyzed current data on myocardial ischemia-reperfusion, the etiopathogenesis of perioperative cardiac complications, recurrence of their development and the possible consequences. It is concluded that prevention and timely treatment of complications resulting from ischemia-reperfusion of the myocardium, with noncardiac surgical interventions is an important tactical (prevention of perioperative myocardial infarction, arrhythmias, cardiac death) and policy (prevention of cardiac remodeling and post-hospital disability of patients) anaesthesiological tasks. Research carried out in the Nrgovsky Research Institute of General Reanimatology showed that in the real practice Detsky index, Lee index and echocardiographic left ventricular ejection fraction did not provide high accuracy prediction of cardiac events. More informative proved preoperative determination of blood N-terminal part of the pro-brain natriuretic peptide (NT-proBNP). In assessing the predictive ability of NT-proBNP area under the ROC-curve achieved 0.86. NT-proBNP value 358 pg/ml and above provided 77% sensitivity and 85% specificity. The comparative assessment and recommendations on the use to reduce the risk of cardiac complications of β-blockers, statins, calcium channel blockers, nitrates, clonidine, dexmedetomidine, levosimendan and phosphocreatine. Phosphocreatine, introduced in practice domestic cardiac surgery and transplantology more than 20 years ago, continues to be studied and used at the moment. Recently demonstrated that perioperative phosphocreatine usage appointment in older oncological patients with a high risk of cardiac complications reduces the incidence of acute ischemia and delirium, shortens the length of stay the intensive care unit and hospital stay. It was concluded that the reduction in the incidence of cardiac events has undoubted relevance with noncardiac operations.

Clinical experience of anesthetic management of orthotopic heart transplantation (OHT) gained at the N.V. Sklifosofsky Research Institute for Emergency Medicine up to date, gives every reason to conclude that combining the knowledge and skills acquired through everyday cardioanesthetic activities, with protocols previously developed in leading transplant clinics, could allow to successfully master the anesthetic management of OHT and make this transplant surgery the standard treatment option. We believe that the use of protocols adapted to our own experience and the latest developments in the field of intensive therapy will allow us to successfully implement the OHT program in a multidisciplinary hospital.

The phenomenon of the contemporary Russian bureaucracy.

The computerized system to control depth of anesthesia during surgical operation was developed in our research center. The depth of anesthesia is regulated by controlled intravenous infusion of propofol. The varied propofol rate is controlled by the closed-loop propofol system (CLPS) with mean arterial pressure (MAP) controller. MAP is used in the CLPS as input parameter and indicator of anesthesia depth. CLPS consists PC, invasive blood pressure (BP) sensor and Graseby 3400 infusion pump. The C language computer program sets the propofol infusion rate based on empirical algorithm including proportional component to maintain the measured MAP more closely to the target MAP (85% of patient standard MAP). The propofol concentrations are calculated by Runge–Kutta’s method PK/PD model differential equations solving with Marsh’s microconstants and Kazama’s BIS effect site microconstant and age depended BP effect site microconstants every 30 s. The designed CLPS was effective and useful for anesthesia maintenance during open-heart surgery, especially for early extubation.

Objective: to study the prognostic value and correlations of hemodynamic parameters during operations under extracorporeal circulation (EC), as well as the possibilities of mathematically predicting the time that takes to recover the normal function of the heart operated on.Subjects and methods: Ninety-three patients (88 males and 5 females) who had undergone myocardial revascularization under EC were examined. The standard intraoperative monitoring involved pulmonary arterial catheterization and transesophageal echocardiography (TEEcho-CG) The duration of postopertative inotropic therapy was recorded. Multiple linear regression analysis was used to comparatively assess the prognostic value of hemodynamic parameters.Results: At the end of surgery, left ventricular ejection fraction, pulmonary artery wedge pressure, and cardiac index were established to be significant predictors of the duration of using cardiotonics. The analysis permitted the prognostic value of the established hemodynamic predictors to be depicted as a linear regression equation. It was shown to be clinically applied.Conclusion. The study revealed the significant intraoperative hemodynamic predictors of recovery of the function of the myocardium after its revascularization under EC. The proposed procedure for interpreting the data obtained, by using a Swan-Ganz catheter and TEEcho-CG, predicts the duration of required sympathomimetic therapy and hence the time of recovery of normal function of the heart operated on.

The experience of surgical treatment of 154 patients having chronic pancreatitis with preferential injury of the pancreas head which underwent different operative interventions: isolated resection of pancreatic head ( based upon Berger surgery - 24, Frey surgery - 39), pancreatoduodenal resection ( with gastric resection - 22, with preserved pylorus - 43) and drainage surgeries - 26 is presented in the article. The surgery of isolated resection of pancreatic head has less number of nearest unfavorable results compared with pancretoduodenal resection with preserved pylorus. Proximal resection of the pancreas the variants of which are different isolated resection of pancreatic head is superior upon surgeries with full or partly resection of the duodenum due to fast normalization of the motor-evacuation function, less rate of the intestinal reflux and portion character of duodenal evacuation. In the follow-up period after pancreatoduodenal resection, atrophic processes occur in distal areas of the pancreas which are followed by clinical manifestations of exo- and endocrinous insufficiency. The surgery of longitudinal pancreatic jejunostomy does not avoid pathologic changes in the organ head and pain syndrome.

Objective: to optimize the transportation of cardiosurgical patients from the operating-room to an intensive care unit (ICU), by developing and introducing a pathogenetically grounded measure to prevent poor circulatory reactions.Materials and methods. 94 patients operated on under extracorporeal circulation for coronary heart disease and transferred to an ICU for sustained artificial ventilation (AV) during moderate sympathomimetic therapy. The patients were prospectively divided into 2 groups: 1) patients who were transported during sympathomimetic therapy selected by the end of an operation; 2) those who were additionally given dobutamine in a dose of 2—3 (2.5±0.01) ^g/kg/min just before putting them from the operating table to the intensive care bed if this drug was not used, or its dosage was increased by 25% of the administered dose. The patients of the identified groups did not differ in age, severity, and undergone operations. In the groups, the sympathomimetic therapy selected by the end of an operation was virtually identical. Central hemodynamics (CHD) and blood oxygen-transporting function (BOTF) were examined before placing the patients from the operating table to the intensive care bed and after referral to the ICU. During transportation, circulatory parameters were recorded every minute and Holter ECG monitoring was done.Results. During transportation blood pressure significantly elevated, cardiac pump function and BOTF parameters decreased. Holter monitoring demonstrated substantial changes that may reflect the activation of the sympathetic and parasympathetic parts of the autonomic nervous system. The use of dobutamine (Group 2) effectively prevented cardiac depression in the patients transferring to the ICU.Conclusion. During transportation of cardiosurgical patients who are on AV and receive moderate sympathomimetic therapy, there may be a worse cardiac pump function due to a complex of autonomic reactions that alter vascular tone and, possibly, myocardial contractility. Dobutamine-induced enhanced inotropic support may prevent circulatory changes.

Objective: to comparatively evaluate the efficiency of intensive care measures chosen on the basis of traditional monitoring of central hemodynamics (CH) or on that of the data of transesophageal echocardiography (TE echoCG).Materials and methods: 50 patients were examined at coronary bypass surgery under extracorporeal circulation. Under a prospective comparative analysis were two algorithms of treatment policy: maintenance of cardiac index, by using the maximum volemic load, or that of left ventricular systolic function under guidance of transesophageal echocardiography.Results: Significantly (p

The present study was undertaken to analyze the efficacy of inhaled nitric oxide (iNO) in the prevention and treatment of intraoperative gas-exchange disorders during operations on the ascending aorta with hypothermal circulatory arrest. The study included 22 patients aged 16—67 years. It revealed that the use of iNO substantially improved arterial oxygenation at surgery with hypothermal circulatory arrest. The preliminary findings suggest that the preventive use of iNO during extracorporeal circulation improves the clinical course of patients after surgery with hypothermal circulatory arrest.

The problem of sedation in intensive care units has obvious scientific-and-practical relevance. Many current studies deal with the practical introduction of novel medications for sedation, with the specific features of their pharmacodynamic effects in different clinical situations, with the advantages and disadvantages of their use. Recent years are marked by an increase in the number of publications on the o^-adrenoceptor agonist dexmedetomidine used for sedation. The paper reviews current publications on o^-adrenoceptor agonists used in anesthesiology and resuscitation, considers their physiology and the mechanism of sedative action of dexmedetomidine, its pharmacokinetics and pharmacodynamics at different plasma concentrations of the drug. The experience in using dexmedetomidine sedation in clinical practice is discussed in detail, by analyzing the data of current multicenter randomized trials in which the drug has been compared with other sedative medications (propofol, midazolam, lorazepam). Some aspects of the clinical pharmacology of dexmedetomidine, such as its effect on the brain and its blood flow, nociception, sympathoadrenal system, hemodynamics, respiratory system, thermoregulation, immunity, and neuroendocrine system, are analyzed. The clinical value of different receptor-dependent effects of the drug and the specific features of its application in different situations are also analyzed. Key words: dexmedetomidine; sedation in intensive care patients; sedative drugs; o^-adrenoceptor agonists; delirium in intensive care unit patients.

Objective: to study the time course of changes in brain natriuretic peptide (BNP) levels in patients with coronary heart disease, who undergo myocardial revascularization under extracorporeal circulation and to assess a relationship of the level of the biomarker to the clinical data in the early postoperative period. Subjects and methods. Fifty-two patients aged 62.2±1.1 years with a left ventricular ejection fraction (LVEF) of 51.1±1.4% were examined. The concentration of BNP was determined by immunofluorescence assay (Triage Meter Plus, Biosite Diagnostics, USA) before (BNP1) and at the end (BNP2) of surgery, in the morning of the first (BNP3) and second (BNP4) postoperative days. Central hemodynamics was invasively monitored using Swan-Ganz-type catheters. Results. The values of the biomarker were normal (51.6±3.5 pg/ml) in most cases. In the other patients, the level of the peptide was increased up to 165.8±16.1 pg/ml. The relationship between preoperative LVEF and BNP1 was moderate (r=-0.54; p

Objective: to study the informative value of a dramatic increase in the preoperative blood level of the inactive moiety of the precursor of N-terminal pro-type B natriuretic peptide (NT-proBNP) in cardiac surgical patients with hypercreatininemia. Subjects and materials. Twenty-one patients with a preoperative NT-proBNP level of 1000 pg/ml or more, who underwent myocardial revascularization under extracorporeal circulation (ECC), were examined. The patients were divided into groups with normal (up to 120 ^mol/l) (Group 1; n=11) and elevated (Group 2; n=10) creatinine concentrations. The values of circulation were processed after skin incision and at the end of surgery. The clinical features of a perioperative period were analyzed. Results. Creatininemia was 103±3.3 and 183±12.9 ^mol/l in Groups 1 and 2, respectively (p0.05). There were no intergroup differences in intraoperative circulatory parameters. The intensity of sympatomimetic therapy after ECC was equal in the identified patient groups and there were either no differences (p>0.05) in the frequency of intra-aortic balloon counterpulsation (18.2 and 10.0%), the length of mechanical ventilation (15±1.5 and 18.7±2.3 hours) and intensive care unit stay (1.8±0.5 and 2.0±0.7 days) in survivors, and inpatient mortality (23.7 and 20.0%) that proved to be substantially higher than the EuroSCORE-predicted one. Regression analysis showed that in the entire group of operated patients, the level of NT-proBNP turned out to be a more significant predictor of inpatient mortality (p=0.012) than EuroSCORE-predicted one (p = 0.04). The similar regularity was characteristic for patients with hypercreatininemia. In the patients with hypercholesterolemia, the EuroSCORE-predicted mortality completely lost its significance (p=0.61) in predicting actual mortality rates. In this group, NT-proBNP showed a predicting trend. Conclusion. The blood NT-proBNP concentration of 1000 pg/ml or more preserves its significance as a high operative risk factor in the presence of myocardial revascularization under ECC in patients with the blood creatinine level of 140—270 ^mol/l. Key words: N-terminal pro-type B natriuretic peptide (NT-proBNP), myocardial revascularization, extracorporeal circulation, hypercreatininemia.

Цель исследования — изучить возможность применения интраоперационной чреспищеводной эхокардиографии для определения показаний и противопоказаний к ранней активизации в операционной после реваскуляризации миокарда в условиях ИК. Материал и методы. Обследовали 186 больных в возрасте 55,0±0,6 лет. Для ультразвукового исследования использовали аппарат Sonos Agilent 5500 и мультиплановый датчик Omni-2 (Philips). Определяли фракцию изгнания левого желудочка в 4-камерной (Simpson) и в трансгастральной позициях (визуализация поперечного сечения левого желудочка на уровне папиллярных мышц). Для выявления нарушений сократительной функции миокарда, препятствующих немедленной активизации, проанализировали данные обследования 142 больных, у которых могла быть выполнена экстубация трахеи в операционной. В качестве противопоказания к активизации рассматривали снижение фракции изгнания левого желудочка в трансгастральной позиции до уровня менее 50%. Чувствительность эхокардиографии в дифференциальной диагностике острого инфаркта миокарда изучили у 44-х больных с электрокардиографическими признаками острого ишемического повреждения сердечной мышцы. Результаты. Значения фракции изгнания левого желудочка в трансгастральной позиции менее 50% (41,5±2,2%) явились критерием отказа от немедленной активизации больных. У этой категории больных более продолжительны, чем у больных с фракцией изгнания левого желудочка 60,1±1,7%, были продолжительность инотропной терапии (45,2±2,1 и 13±1,1 ч; р

Objective: to study the efficacy of inhaled nitric oxide used intraoperatively to prevent lung oxygenating dysfunction in patients with coronary heart disease after myocardial revascularization under extracorporeal circulation (EC). Subjects and methods. Thirty-two patients aged 55.0±2.0 years were examined. The inclusion criteria were the standard course of surgical intervention (the absence of hemorrhage, acute cardiovascular insufficiency, perioperative myocardial infarction, etc.), a pulmonary artery wedge pressure of less than 15 – mm Hg throughout the study, and the baseline arterial partial oxygen tension/inspired mixture oxygen fraction (PaO2/FiO2) ratio of at least 350 mm Hg. There was a control group (n=21; Group 1) that used no special measures to prevent and/or to correct lung oxygenating dysfunction and Group 2 (n=11) that received inhaled nitric oxide. Ihe administration of inhaled nitric oxide at a concentration of 10 ppm was initiated after water anesthesia, stopped during EC, and resumed in the postperfusion period. Results. At the end, PaO2/FiO2 and intrapulmonary shunt fraction did not differ between the groups (p>0.05). Before EC, the patients receiving inhaled nitric oxide had a lower intrapulmonary blood shunting (8.9±0.7 and 11.7±1.0%; p

In foreign countries, the anesthesiological and resuscitative tactics that ensure the maximally rapid discontinuation of mechanical ventilation are regarded as a fundamental therapeutic component of the so-called fast-track cardiac surgery that provides a shorter length of hospital stay, an intensified therapeutic process, and lower-cost treatment. In the Russian literature, this methodic approach is customarily designated early activation, by bearing in mind that discontinuation of mechanical ventilation is a key point of postoperative recovery of the patients’ physical activity. The main Russian and foreign publications on the specific features of therapeutic tactics in early periods after cardiac surgery are historically analyzed. The paper covers the polemic between the supporters and opponents of the earliest activation of patients operated on under extracorporeal circulation, the change of views on a need for obligatory postoperative mechanical ventilation, and the impact of the rate of activation and physical activity on the quality of rehabilitation. Terminology and clinicians’ points of views on the optimum activation periods are analyzed. Key words: early activation, operations under extracorporeal circulation, tracheal extubation in an operating room, early tracheal extubation, postoperative rehabilitation of cardiosurgical patients.

Objective: to reveal the predictors of clinically significant deterioration of cardiac pump function resulting from alveolar opening maneuver (AOM) (mobilization) made early after extracorporeal circulation during standard cardiosurgery. Subjects and methods. Hemodynamic, clinical, and laboratory parameters were analyzed in 20 cardiosurgical patients who had undergone AOM in the early postperfusion period. The study inclusion criteria were a PaO2/FiO2 ratio of less than 350 mm Hg, a cardiac index (CI) of more than 2.5 l/min/m2, a dosage of dopamine and/or dobutamine of not more than 10 μg/kg/min, and standard AOM performance (Pmax, 30—35 cm H2O; endexpiratory pressure (PEEP), 13—15 cm H2O). Regression analysis was used to identify the predictors of a clinically significant reduction in CI (less than 2.5 l/min/m2). Results. Before and after AOM, CI was 3.1±0.1 and 2.9±0.1 l/min/m2, respectively (p>0.05); however, CI was less than 2.5 l/min/m2 (2.16±0.09 l/min/m2) in 25% of cases. After AOM, CI values were significantly related to those recorded prior to a respiratory procedure (p=0.039), total peripheral vascular resistance index (TPVRI) (p=0.00039), and intrapulmonary blood shunt fraction (Qs/Qt) (p=0.041). There were no relationships to other recorded and estimated hemodynamic parameters (p>0.1). After AOM, CI values were unrelated (p>0.1) to the duration of extracorporeal circulation, the period of myocardial ischemia, and the used dosages of inotropic agents. The predictor of a clinically significant CI reduction after AOM was the only index TPVRI (p=0.00025) recorded before a respiratory procedure. Following AOM, the probability of a significant CI reduction substantially increased (the approximation coefficient R2=0.75) at TPVRI values of 2000 din•sec•cm-5•m2 or more. Conclusion. After AOM performed in the early period after extracorporeal circulation, CI values are related to the baseline level of CI, TPVRI, and Qs/Qt; however, after this procedure only the value of TPVRI is a reliable predictor of clinically significantly depressed cardiac pump function. The risk of persistent cardiodepression is highest at TPVRI values of 2000 din•sec•cm-5•m2 or more. AOM should be carried out early after extracorporeal circulation in cardiosurgical patients, by making an invasive monitoring that makes it possible to maximally correctly evaluate central hemodynamics, including CI and TPVRI.

Objective: to study the impact of increased inactive (N-terminal) pro-B-type natriuretic peptide (NT-proBNP) levels in cardiosurgical patients with coronary heart disease without drastically reducing left ventricular contractility on intraoperative central hemodynamics and the specific features of therapeutic measures for its stabilization. Subjects and methods. The inclusion criteria were elective surgery, age less than 70 years, a left ventricular ejection fraction of at least 30%, and no surgical complications. Sixty-one patients aged 54.6±1.2 years with a left ventricular ejection fraction of 51. 5 ± 1. 6 %. Before surgery, NT-proBNP was determined by electrochemiluminiscence («Elescys®proBNP»). Invasive hemodynamic monitoring was made with Swan-Ganz catheters. Results. The level of NT-proBNP was 13.2—3232 pg/ml. When the preperfusion values of the biomarker was more than 350 pg/ml, the magnitude of a peptide concentration increase affected that of an elevation of pulmonary artery wedge pressure (r=0.52; p=0.002) and that of a decrease in left ventricular pump coefficient (r=-0.44; p=0.01). At the end of operations, this patient group, as compared with the others, had a lower left ventricular pump coefficient (2.9±0.2 and 3.9±0.3 g/mm Hg/m2; p

Objective: to study the specific features of oxygen transport function in patients with various oxygen delivery changes caused by alveolar opening maneuver (mobilization) performed early after extracorporeal circulation. Subjects and methods. Alveolar opening maneuver was made in the presence of relative arterial hypoxemia under the control of dynamic thora-copulmonary compliance. The maximum airway pressure was as high as 31.1±0.3 cm H2O; the positive end-expiratory pressure was 16.0±0.3 cm H2O. According to the changes in oxygen delivery after alveolar opening maneuver, the investigators retrospectively identified the following groups: 1) (n=14) with a lower and 2) (n=15) higher values. The groups did not differ in age (53.6±2.8 and 56.4±1.8 years), extracorporeal circulation duration (106.4±11.2 and 86.8±4 min), and inotropic support intensity (4.7±0.5 and 4.6±0.6 ^g/kh/min for dopamine and/or dobutamine) (p>0.05). The mode of alveolar opening maneuver and its impact on thoracopulmonary compliance and pulmonary oxygenizing function were identical in the groups (p>0.05). Results. 48.3% of the patients with relative arterial hypoxemia show a linear relationship between the oxygen delivery and consumption indices (r=0.73; p=0.003), and there was a close inverse correlation between the oxygen utilization coefficient and intrapulmonary shunting (r=-0.77; p=0.001). After alveolar opening maneuver, the oxygen delivery index decreased in these cases from 440.7±31.7 to 376.9±20.4 ml/min/m2 (p

Objective: to study central hemodynamics, the determinants of coronary blood flow and myocardial oxygen demand, and the parameters of blood oxygen-transport function during alveolar mobilization in early periods after extracorporeal circulation in patients operated on for coronary heart disease. Subjects and methods. Twenty-nine patients were examined after myocardial revascularization. The alveolae were mobilized 63±2 min after extracorporeal circulation. The peak airway pressure was 31±0.3 H2O. Invasive hemodynamic monitoring was provided with Swan-Ganz catheters. Results. After building up the peak airway pressure, there was a 7.5—15 mm Hg blood pressure reduction (p

Objective: to make a complex analysis of the efficacy of xenon as the major agent in maintaining anesthesia during early activation of patients operated on under extracorporeal circulation for coronary heart disease. Subjects and methods. Forty-two patients aged 59±3 years were examined. A total of 3±0.2 coronary arteries were shunted. General anesthesia was induced and maintained by propofol and fentanyl under extracorporeal circulation. Anesthesia was maintained by xenon inhalation in the preperfusion and postperfusion periods. General anesthesia was combined with high (Th3—Th4) epidural anesthesia in 10 cases. Results. During xenon inhalation, the central hemodynamic parameters were maximally steady-state both before and after extracorporeal circulation. The coronary perfusion conditions estimated from the coronary perfusion gradients were stable. The study of the conditions for coronary perfusion and the values of myocardial demand showed the persistence of their balance (r=0.55—0.83; p

Objective: to study the plasma content of B-type natriuretic peptides in coronary heart disease patients prepared for surgery under extracorporeal circulation and to assess the association of the level of these biomarkers with the data of clinical and functional studies. Material and methods. The levels of active B-type natriuretic peptide were determined by immunofluoresence assay in the blood of 52 patients aged 57.8±1 years. The patients’ baseline clinical condition was in New York Heart Association (NYHA) Functional Class I—IV. The left ventricular ejection fraction was 59.6±1.2%. The plasma concentration of the inactive N-terminal fragment of the BNP prohormone (NT-proBNP) was estimated by electric chemiluminescence technique in 61 patients aged 54.6±1.18 years. The patients’ clinical condition was in NYHA Functional Class II—IV. The left ventricular ejection fraction was 51.5±1.6%. Results. The plasma content of B-type natriuretic peptide in the examinees was 48.5±5.9 pg/ml. The level of the biomarker correlated with the NYHA functional class (r=0.4; p=0.005), the electrocardiographic signs of postinfarct cardiosclerosis (r=0.29; p=0.04), and left ventricular ejection fraction (r=-0.41; p=0.003), and end-systolic volume (r=0.32; p=0.03). The plasma concentration of inactive NT-proBNP was 659.4±91.6 pg/ml. The level of the biomarker correlated with the NYHA functional class (r=0.4; p=0.002), the stage of circulatory insufficiency as described by I. D. Strazhesko and V. Kh. Vasilenko (r=0.49; p=0.001), and left ventricular ejection fraction (r=-0.45; p=0.001), and end-diastolic (r=0.39; p=0.002) and end-systolic (r=0.42; p=0.001) volumes. In patients with the values of the biomarker of less than 1000 pg/ml, the latter was related to age (r=0.3; p=0.047). Conclusion. The study of the level of B-type natriuretic peptides in cardiosurgical patients with coronary heart disease, prepared for surgery under extracorporeal circulation, suggests that the content of both peptides is obviously correlated with the conventional clinicofunctional parameters. At the same time, the moderate or weak pattern of all correlations indicated the independent diagnostic value of biomarkers. Key words: B-type natriuretic peptides, brain nautri-uretic peptide (BNP), N-terminal fragment of the BNP prohormone (NT-proBNP), coronary heart disease, surgery under extracorporeal circulation.